NAMES AND DATABASE IDS
NAMES AND DATABASE IDS
Names Database IDs
IUPAC name
|
2-hydroxy-5-[(E)-2-{4-[(pyridin-2-yl)sulfamoyl]phenyl}diazen-1-yl]benzoic acid
|
2-hydroxy-5-(2-{4-[(pyridin-2-yl)sulfamoyl]phenyl}diazen-1-yl)benzoic acid
|
|
|
IUPAC Traditional name
|
sulfasalazine
|
@sulfasalazine
|
|
|
Brand Name
|
Accucol
|
Alti-Sulfasalazine
|
Asulfidine
|
Azlufidine EN-Tabs
|
Azopyrin
|
Azopyrine
|
Azulfidine
|
Azulfidine EN-Tabs
|
Benzosulfa
|
Colo-Pleon
|
PMS-Sulfasalazine
|
Pms-Sulfasalazine E.C.
|
Reupirin
|
Rorasul
|
S.A.S. Enteric-500
|
Salazopiridazin
|
Salazopyridin
|
Salazopyrin
|
Salazopyrin EN-Tabs
|
Salazosulfapyridin
|
Salazosulfapyridine
|
Salicylazosulfapyridine
|
Salisulf
|
Sulcolon
|
W-T Sasp Oral
|
|
|
Synonyms
|
Sulfasalazine
|
5-[4-(2-Pyridylsulfamoyl)phenylazo]salicylic acid
|
Sulphasalazine
|
Sulfasalazin
|
2-Hydroxy-5-[[4-[(2-pyridinylamino)sulfonyl]phenyl]azo]benzoic Acid
|
5-[[p-(2-Pyridylsulfamoyl)phenyl]azo]salicylic Acid
|
5-[p-(2-Pyridylsulfamyl)phenylazo]salicylic Acid
|
Azopyrin
|
Azopyrine
|
Azulfidine
|
Azulfidine EN
|
Benzosulfa
|
Colo-Pleon
|
NSC 203730
|
NSC 667219
|
Reupirin
|
Salazopyridin
|
Salazopyrin
|
Salazopyrine
|
Salazosulfapyridin
|
Salazosulfapyridine
|
Salicylazosulfapyridine
|
Salisulf
|
2-hydroxy-5-(2-{4-[(pyridin-2-yl)sulfamoyl]phenyl}diazen-1-yl)benzoic acid
|
Sulfasalazine
|
2-HYDROXY-(5-([4-(2-PYRIDINYLAMINO)SULFONYL]PHENYL)AZO)BENZOIC ACID
|
5-(p-(2-Pyridinylsulfamoyl)Phenylazo)Salicylic Acid
|
Sulfasalazine (Azulfidine)
|
5-[对-(2-吡啶胺磺酰基)苯]偶氮水杨酸
|
柳氮磺胺吡啶
|
|
|
CAS Number
|
|
EC Number
|
|
MDL Number
|
|
Beilstein Number
|
|
PubChem SID
|
|
PubChem CID
|
|
DATA SOURCES
DATA SOURCES
All Sources Commercial Sources Non-commercial Sources
CALCULATED PROPERTIES
CALCULATED PROPERTIES
JChem
ALOGPS 2.1
Acid pKa
|
3.2977388
|
H Acceptors
|
8
|
H Donor
|
3
|
LogD (pH = 5.5)
|
1.9754564
|
LogD (pH = 7.4)
|
0.2490507
|
Log P
|
3.9374347
|
Molar Refractivity
|
104.6029 cm3
|
Polarizability
|
38.550716 Å3
|
Polar Surface Area
|
141.31 Å2
|
Rotatable Bonds
|
5
|
Lipinski's Rule of Five
|
true
|
Log P
|
2.92
|
LOG S
|
-3.93
|
Solubility (Water)
|
4.64e-02 g/l
|
DETAILS
DETAILS
MP Biomedicals
DrugBank
Sigma Aldrich
TRC
DrugBank -
DB08518
|
Drug information: experimental |
DrugBank -
DB00795
|
Item |
Information |
Drug Groups
|
approved |
Description
|
A drug that is used in the management of inflammatory bowel diseases. Its activity is generally considered to lie in its metabolic breakdown product, 5-aminosalicylic acid (see mesalamine) released in the colon. (From Martindale, The Extra Pharmacopoeia, 30th ed, p907) |
Indication |
For the treatment of Crohn's disease and rheumatoid arthritis as a second-line agent. |
Pharmacology |
Sulfasalazine is an anti-inflammatory indicated for the treatment of ulcerative colitis and rheumatoid arthritis. |
Affected Organisms |
• |
Humans and other mammals |
|
Half Life |
5-10 hours |
Elimination |
The majority of 5-ASA stays within the colonic lumen and is excreted as 5-ASA and acetyl-5-ASA with the feces. |
Distribution |
* 7.5 ± 1.6 L |
Clearance |
* 1 L/h [IV administration] |
External Links |
|
|
REFERENCES
REFERENCES
From Suppliers
Google Scholar
PubMed
Google Books
- • Schroder, H., et al.: Clin. Pharmacol. Ther.,13, 539 (1972)
- • McDonnell, J.P., et al.: Anal. Profiles Drug Subs., 5, 515 (1972)
- • Klotz, U., et al.: Clin. Pharmacokinet.,10, 285 (1972)
- Searching...Please wait...
PATENTS
PATENTS
PubChem Patent
Google Patent